Impacts of protease inhibitors on clathrin and fibronectin in cancer metastasis

Chih I. Wu, Ming Min Chang, Chun Li Su, Pin Ling, Wen Tsan Chang, Hung Chi Cheng

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Metastasis is a major cause of cancer deaths. Seeking alternative prognostic biomarkers may enable oncologists to make accurate therapeutic decisions to benefit cancer patients. Cumulated evidence reveals that fibronectin (FN) is highly correlated with cancer metastasis but has not been deemed as a prognostic biomarker due to its broad tissue distribution patterns and complicated physiological and pathological functionalities that significantly interfere with the judgmental accuracy. Combining other FN-related factors may make FN possible as a useful prognostic biomarker. Clathrin, a highly protease-susceptible cytoplasmic molecule, is known to affect pericellular FN (periFN) assembly via regulating cell surface FN receptors or FN matrix turnover by coating the endocytic vesicles. Researching our previously published proteomics database of 660 differential secretome proteins expressed in human lung adenocarcinoma cell lines and performing double immunofluorescent staining for periFN and clathrin, we recognized an inverse relationship between them. However, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) data contradicted this relationship, which could be corrected by the addition of a mixture of protease inhibitors into nonmetastatic cancer cell lysates. These results suggested that nonmetastatic cells express either higher levels of cellular proteases or less amounts of protease inhibitors. By examining our proteomic database and reviewing the literature, we conclude that clathrin expression and assembly is inversely correlated with metastatic potential of FNhigh cancer cells mainly related to the expression of protease inhibitors, instead of proteases. It is worth investigating whether such an inverse relationship between FN/protease inhibitors and clathrin in human cancers could clinically be incorporated into the prognostic strategy for various cancer types.

Original languageEnglish
Pages (from-to)23-31
Number of pages9
JournalBiomarkers and Genomic Medicine
Volume6
Issue number1
DOIs
Publication statusPublished - 2014 Mar

Fingerprint

Clathrin
Protease Inhibitors
Fibronectins
Neoplasm Metastasis
Biomarkers
Neoplasms
Peptide Hydrolases
Cells
Proteomics
Fibronectin Receptors
Databases
Transport Vesicles
Electrophoresis
Sodium Dodecyl Sulfate
Sodium dodecyl sulfate
Tissue Distribution
Polyacrylates
Polyacrylamide Gel Electrophoresis
Cause of Death
Tissue

Keywords

  • Cancer metastasis
  • Clathrin
  • Fibronectin
  • Prognostic biomarkers
  • Protease inhibitors

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biochemistry, Genetics and Molecular Biology(all)
  • Drug Discovery

Cite this

Impacts of protease inhibitors on clathrin and fibronectin in cancer metastasis. / Wu, Chih I.; Chang, Ming Min; Su, Chun Li; Ling, Pin; Chang, Wen Tsan; Cheng, Hung Chi.

In: Biomarkers and Genomic Medicine, Vol. 6, No. 1, 03.2014, p. 23-31.

Research output: Contribution to journalReview article

Wu, Chih I. ; Chang, Ming Min ; Su, Chun Li ; Ling, Pin ; Chang, Wen Tsan ; Cheng, Hung Chi. / Impacts of protease inhibitors on clathrin and fibronectin in cancer metastasis. In: Biomarkers and Genomic Medicine. 2014 ; Vol. 6, No. 1. pp. 23-31.
@article{4cb581d931bc4ed4ac2acf7794bb9856,
title = "Impacts of protease inhibitors on clathrin and fibronectin in cancer metastasis",
abstract = "Metastasis is a major cause of cancer deaths. Seeking alternative prognostic biomarkers may enable oncologists to make accurate therapeutic decisions to benefit cancer patients. Cumulated evidence reveals that fibronectin (FN) is highly correlated with cancer metastasis but has not been deemed as a prognostic biomarker due to its broad tissue distribution patterns and complicated physiological and pathological functionalities that significantly interfere with the judgmental accuracy. Combining other FN-related factors may make FN possible as a useful prognostic biomarker. Clathrin, a highly protease-susceptible cytoplasmic molecule, is known to affect pericellular FN (periFN) assembly via regulating cell surface FN receptors or FN matrix turnover by coating the endocytic vesicles. Researching our previously published proteomics database of 660 differential secretome proteins expressed in human lung adenocarcinoma cell lines and performing double immunofluorescent staining for periFN and clathrin, we recognized an inverse relationship between them. However, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) data contradicted this relationship, which could be corrected by the addition of a mixture of protease inhibitors into nonmetastatic cancer cell lysates. These results suggested that nonmetastatic cells express either higher levels of cellular proteases or less amounts of protease inhibitors. By examining our proteomic database and reviewing the literature, we conclude that clathrin expression and assembly is inversely correlated with metastatic potential of FNhigh cancer cells mainly related to the expression of protease inhibitors, instead of proteases. It is worth investigating whether such an inverse relationship between FN/protease inhibitors and clathrin in human cancers could clinically be incorporated into the prognostic strategy for various cancer types.",
keywords = "Cancer metastasis, Clathrin, Fibronectin, Prognostic biomarkers, Protease inhibitors",
author = "Wu, {Chih I.} and Chang, {Ming Min} and Su, {Chun Li} and Pin Ling and Chang, {Wen Tsan} and Cheng, {Hung Chi}",
year = "2014",
month = "3",
doi = "10.1016/j.bgm.2014.02.002",
language = "English",
volume = "6",
pages = "23--31",
journal = "Genomic Medicine, Biomarkers, and Health Sciences",
issn = "2214-0247",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Impacts of protease inhibitors on clathrin and fibronectin in cancer metastasis

AU - Wu, Chih I.

AU - Chang, Ming Min

AU - Su, Chun Li

AU - Ling, Pin

AU - Chang, Wen Tsan

AU - Cheng, Hung Chi

PY - 2014/3

Y1 - 2014/3

N2 - Metastasis is a major cause of cancer deaths. Seeking alternative prognostic biomarkers may enable oncologists to make accurate therapeutic decisions to benefit cancer patients. Cumulated evidence reveals that fibronectin (FN) is highly correlated with cancer metastasis but has not been deemed as a prognostic biomarker due to its broad tissue distribution patterns and complicated physiological and pathological functionalities that significantly interfere with the judgmental accuracy. Combining other FN-related factors may make FN possible as a useful prognostic biomarker. Clathrin, a highly protease-susceptible cytoplasmic molecule, is known to affect pericellular FN (periFN) assembly via regulating cell surface FN receptors or FN matrix turnover by coating the endocytic vesicles. Researching our previously published proteomics database of 660 differential secretome proteins expressed in human lung adenocarcinoma cell lines and performing double immunofluorescent staining for periFN and clathrin, we recognized an inverse relationship between them. However, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) data contradicted this relationship, which could be corrected by the addition of a mixture of protease inhibitors into nonmetastatic cancer cell lysates. These results suggested that nonmetastatic cells express either higher levels of cellular proteases or less amounts of protease inhibitors. By examining our proteomic database and reviewing the literature, we conclude that clathrin expression and assembly is inversely correlated with metastatic potential of FNhigh cancer cells mainly related to the expression of protease inhibitors, instead of proteases. It is worth investigating whether such an inverse relationship between FN/protease inhibitors and clathrin in human cancers could clinically be incorporated into the prognostic strategy for various cancer types.

AB - Metastasis is a major cause of cancer deaths. Seeking alternative prognostic biomarkers may enable oncologists to make accurate therapeutic decisions to benefit cancer patients. Cumulated evidence reveals that fibronectin (FN) is highly correlated with cancer metastasis but has not been deemed as a prognostic biomarker due to its broad tissue distribution patterns and complicated physiological and pathological functionalities that significantly interfere with the judgmental accuracy. Combining other FN-related factors may make FN possible as a useful prognostic biomarker. Clathrin, a highly protease-susceptible cytoplasmic molecule, is known to affect pericellular FN (periFN) assembly via regulating cell surface FN receptors or FN matrix turnover by coating the endocytic vesicles. Researching our previously published proteomics database of 660 differential secretome proteins expressed in human lung adenocarcinoma cell lines and performing double immunofluorescent staining for periFN and clathrin, we recognized an inverse relationship between them. However, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) data contradicted this relationship, which could be corrected by the addition of a mixture of protease inhibitors into nonmetastatic cancer cell lysates. These results suggested that nonmetastatic cells express either higher levels of cellular proteases or less amounts of protease inhibitors. By examining our proteomic database and reviewing the literature, we conclude that clathrin expression and assembly is inversely correlated with metastatic potential of FNhigh cancer cells mainly related to the expression of protease inhibitors, instead of proteases. It is worth investigating whether such an inverse relationship between FN/protease inhibitors and clathrin in human cancers could clinically be incorporated into the prognostic strategy for various cancer types.

KW - Cancer metastasis

KW - Clathrin

KW - Fibronectin

KW - Prognostic biomarkers

KW - Protease inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84897964815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897964815&partnerID=8YFLogxK

U2 - 10.1016/j.bgm.2014.02.002

DO - 10.1016/j.bgm.2014.02.002

M3 - Review article

AN - SCOPUS:84897964815

VL - 6

SP - 23

EP - 31

JO - Genomic Medicine, Biomarkers, and Health Sciences

JF - Genomic Medicine, Biomarkers, and Health Sciences

SN - 2214-0247

IS - 1

ER -